Patrick F Joyce

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Holly M Horton, Eugene A Zhukovsky, John R Desjarlais, 2008, Cancer research.

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.

G. A. Lazar, John R Desjarlais, Igor Vostiar, 2008, Molecular immunology.